Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Gains from Investment Securities (2019 - 2025)

Allogene Therapeutics' Gains from Investment Securities history spans 6 years, with the latest figure at $425000.0 for Q2 2025.

  • For Q2 2025, Gains from Investment Securities fell 88.97% year-over-year to $425000.0; the TTM value through Sep 2025 reached -$452000.0, down 118.76%, while the annual FY2024 figure was $2.0 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q2 2025 was $425000.0 at Allogene Therapeutics, up from -$425000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $28.2 million in Q2 2022 and bottomed at -$15.3 million in Q2 2021.
  • The 4-year median for Gains from Investment Securities is $425000.0 (2025), against an average of $4.9 million.
  • The largest YoY upside for Gains from Investment Securities was 27861.4% in 2021 against a maximum downside of 507.48% in 2021.
  • A 4-year view of Gains from Investment Securities shows it stood at $20.1 million in 2021, then skyrocketed by 40.68% to $28.2 million in 2022, then tumbled by 101.6% to -$452000.0 in 2024, then skyrocketed by 194.03% to $425000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Gains from Investment Securities are $425000.0 (Q2 2025), -$425000.0 (Q1 2025), and -$452000.0 (Q4 2024).